Differential MicroRNA-34a Expression and Tumor Suppressor Function in Retinoblastoma Cells
Overview
Affiliations
Purpose: The role of miR-34a, a p53-regulated microRNA, in retinoblastoma (RB) was investigated.
Methods: The expression of miR-34 family members in RB cells was determined by semiquantitative RT-PCR and real-time qPCR. Regulation of miR-34a expression by p53-activating compounds was determined by qPCR analysis. The tumor suppressor functions of miR-34a in RB cell lines were determined by tetrazolium-based cell growth assay and by caspase-3/7 and activated caspase-3 apoptotic activity assays. Additive growth inhibitory properties of miR-34a in combination with topotecan were determined by cell growth assay. miR-34a targets in RB cells were identified by real-time qPCR expression analysis of previously reported and GenMiR++-predicted mRNAs.
Results: Differential miR-34a and miR-34b expression was observed in RB cell lines and tumor samples. miR-34a expression could be increased in Y79 cells, but not Weri-Rb1 cells, after p53 activation. This differential regulation was not caused by genomic alterations at the miR-34a p53 binding site or mature gene. Exogenous miR-34a inhibited Y79 and Weri-Rb1 cell growth and increased apoptotic activity in Y79 cells. Increased inhibition of Y79 and Weri-Rb1 cell growth was observed with combination miR-34a and topotecan treatment. mRNA expression changes were observed in 7 of 7 previously reported and 13 of 18 GenMiR++-predicted miR-34a targets after transfection of Y79 cells with miR-34a compared with negative control microRNA.
Conclusions: miR-34a functions as a tumor suppressor in RB cells and is a potential therapeutic target. Differential expression, regulation, and activity of miR-34a in RB cells may suggest further p53 pathway inactivation in RB.
Xie Y, Wu F, Chen Z, Hou Y Biomark Med. 2024; 18(21-22):995-1005.
PMID: 39469853 PMC: 11633390. DOI: 10.1080/17520363.2024.2416887.
MYC Causes Multiple Myeloma Progression via Attenuating TP53-Induced MicroRNA-34 Expression.
Murakami Y, Kimura-Masuda K, Oda T, Matsumura I, Masuda Y, Ishihara R Genes (Basel). 2023; 14(1).
PMID: 36672841 PMC: 9859619. DOI: 10.3390/genes14010100.
Wen Y, Zhu M, Zhang X, Xiao H, Wei Y, Zhao P Transl Cancer Res. 2022; 11(7):2225-2237.
PMID: 35966326 PMC: 9372260. DOI: 10.21037/tcr-21-1748.
miR-200a-3p facilitates bladder cancer cell proliferation by targeting the gene.
Wan P, Chen Z, Huang M, Jiang H, Wu H, Zhong K Transl Androl Urol. 2022; 10(11):4262-4274.
PMID: 34984191 PMC: 8661264. DOI: 10.21037/tau-21-941.
Guo L, Bai Y, Ni T, Li Y, Cao R, Ji S Int J Oncol. 2021; 59(1).
PMID: 34036380 PMC: 8143749. DOI: 10.3892/ijo.2021.5227.